Bio-Rad Laboratories Class A
274 hedge funds and large institutions have $3.8B invested in Bio-Rad Laboratories Class A in 2017 Q1 according to their latest regulatory filings, with 48 funds opening new positions, 105 increasing their positions, 84 reducing their positions, and 26 closing their positions.
85% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 26
25% more funds holding in top 10
Funds holding in top 10: 8 → 10 (+2)
25% more repeat investments, than reductions
Existing positions increased: 105 | Existing positions reduced: 84
6% more capital invested
Capital invested by funds: $3.6B → $3.8B (+$202M)
5% more funds holding
Funds holding: 260 → 274 (+14)
2.9% less ownership
Funds ownership: 80.77% → 77.87% (-2.9%)
99% less call options, than puts
Call options by funds: $638K | Put options by funds: $99.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$330M |
| 2 |
CM
Corvex Management
New York
|
+$69.3M |
| 3 |
HCM
Hitchwood Capital Management
New York
|
+$57.8M |
| 4 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
+$23.4M |
| 5 |
CRM
Cramer Rosenthal McGlynn
Stamford,
Connecticut
|
+$19.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$154M |
| 2 |
LCS
Levin Capital Strategies
New York
|
-$48.8M |
| 3 |
AI
Ariel Investments
Chicago,
Illinois
|
-$40.9M |
| 4 |
TSW
Thompson Siegel & Walmsley
Richmond,
Virginia
|
-$39.6M |
| 5 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$30.3M |
BIO Hedge Fund Activity: Q1 2017 in Review
274 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q1 2017, worth a combined $3.8B — up 5.6% from $3.6B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new BIO positions and 26 closed out — a net gain of 22 holders — while 105 added to existing stakes and 84 trimmed.
The largest buyer was BlackRock, adding an estimated $330M. The largest seller was Morgan Stanley, cutting an estimated $154M.
- 274 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q1 2017, up from 260 in Q4 2016.
- Funds reported $3.8B of Bio-Rad Laboratories Class A stock for Q1 2017, up 5.6% quarter-over-quarter.
- 48 funds opened new Bio-Rad Laboratories Class A positions in Q1 2017 and 26 closed out, a net change of +22 holders.
- The largest Bio-Rad Laboratories Class A buyer in Q1 2017 was BlackRock, an estimated $330M added.
- The largest Bio-Rad Laboratories Class A seller in Q1 2017 was Morgan Stanley, an estimated $154M sold.
Based on aggregated 13F filings for Q1 2017.